Roland Magnusson/iStock Editorial via Getty Images
AstraZeneca (Nasdaq: AZNAddition to chemotherapy, Tagrisso said, helped improve progression-free survival (PFS) in patients with a type of non-small cell lung cancer (NSCLC) in a phase III trial.
The late-stage study, called FLAURA2, enrolled 586 patients with locally advanced (stage 3B-3C) or metastatic (stage 4) epidermal growth factor receptor (EGFRm) NSCLC.
The British pharmaceutical giant said that Tagrisso (osemertinib) in combination with chemotherapy showed a statistically significant and clinically meaningful improvement in PFS, compared to Tagrisso alone.
PFS is the length of time during/after treatment that a patient lives without the disease getting worse.
The company noted that at the time of the analysis, the overall survival (OS) data was immature and would be evaluated in a further analysis.
“The important FLAURA2 results show that Tagrisso has the potential to offer patients a new treatment option in the first phase of treatment that can extend the time they live without disease progression. This usefully builds on back-to-back trials showing improved clinical benefit with Tagrisso in patients with EGFR-mutated lung cancer. He said Susan Galbraith, Executive Vice President, Oncology Research and Development, AstraZeneca.
Safety outcomes and rates of discontinuation due to adverse events were consistent with each drug’s profiles, according to the company.
In March, AstraZeneca reported the results of a phase III trial called ADAURA that showed that Tagrisso helped improve overall survival in patients with early-stage EGFRm NSCLC after complete tumor resection.
